New Nasdaq Biotech Breakout Alert (HUGE) Gets $6.00 Price Target (650% Upside)

New Premium Breakout Alert FSD Pharma (NASDAQ: HUGE) "Reports Positive Phase-1 MS Drug Trials Results" [Analyst Singular Research Predicts This $.80/Pharma]( [Stock as $6 Target Price]( 10XProTrader, This is Kevin Vander with "10XProTrader" delivering you your new Premium Biotech Breakout Alert for Monday 3/11 trading session FSD Pharma (NASDAQ: HUGE). The Company has several bullish catalysts in the pipeline and is on the verge of disrupting multiple Bln-Dlr markets! Bullish Catalyst Singular Research Initiated Coverage of FSD Pharma (NASDAQ: HUGE) Issues Buy Rating with a $6.00 Price Target [ See Analyst Prediction of 650% Upside Here ]( Initiating with Buy Rating and $6.00 PT FSD Pharma (NASDAQ: HUGE) is poised to achieve substantial growth and market penetration according to Wall Street Analyst at Singular Research who Initiated Coverage of FSD Pharma with Buy Rating and $6.00 Price Target. FSD Pharma has 650% upside potential, based on the analysts' price target. All About FSD Pharma, Inc. FSD Pharma Inc. (NASDAQ: HUGE) is a clinical-stage biotechnology company with a robust pipeline of innovative treatments focused on addressing significant unmet needs in brain disorders and alc∙ohol health. The Company has two candidates in different stages of development – 1) Lucid-MS, a proprietary new che∙mical entity targeting progressive multiple sclerosis (MS); and 2), Unbuzzd™, a proprietary formulation of natural ingredients, vitamins, and minerals which helps to accelerate alco∙hol metabolism to reduce blood alc∙ohol Content. FSD Pharma’s functional beverage drink, Unbuzzd™ is targeting to address the huge unmet need for providing relief from inebriation and accelerating alc∙ohol metabolism. Unbuzzd™ is a proprietary formulation of natural ingredients, vitamins, and minerals which helps to accelerate alc∙ohol metabolism to reduce Breath Alc∙ohol Concentration (BrAC). Unbuzzd™ supports the function of the liver and brain in rapidly alleviating the inebriation effects of alc∙ohol intake. The Company will target consumer and hospital markets with this product which is targeted for commercial launch in Q1:24. Unbuzzd™ is better than the hangover cure products currently available in the market. Hangover products are typically used for relief from the night-after alc∙ohol consumption. In contrast, Unbuzzd™ is effective within the first hour after alc∙ohol consumption, and could open totally new avenues for HUGE including hospitals. We note that it takes more than one hour to process one drink of alc∙ohol and only time can lower blood alc∙ohol concentration (BAC). Thus, there is a vast oppor∙tunity for novel products that can help one so∙ber up quickly. According to Grand View Research, the total global hangover products market could reach $4.67 Bln by 2028.1 On the B2B side, hospitals present a large oppor∙tunity. Inebriated consumers with high blood alc∙ohol levels often present to hospital emergency rooms in a variety of contexts. Management of these patients often consume significant staff time and other resources. As such, anything that could accelerate the recovery from ineb∙riation would free up valuable healthcare resources. FSD Pharma has sold the licensing rights of Unbuzzd™ to Celly Nutrition Inc. (Celly Nu) for the consumer market and in turn will receive royalty payments on future sales. Celly Nu has put a world-class team in charge of the product. These members include marketing icon Kevin Harrington and former Celsius Holdings, Inc. CEO Gerry David, who cumulatively have generated bill∙ions of do∙llars of sa∙les and value for brands and shareholders. Mr. David will be Chairman of Celly Nu and is best known for his five-year tenure as Chief Executive Officer at zero-calorie fitness drink maker Celsius Holdings, Inc. where he spearheaded a turnaround that resulted in a global sales explosion, influx of capital from notable strategic investors, and a rise in market capita∙lization that increased shareholder value 35-fold by exceeding $9 Bln. During his career, Kevin Harrington has launched over 1,000 products in over 100 countries generating over $6 Bln in sales. The Team behind UNBUZZD™ Kevin Harrington - Marketing Guru and the original "shark" on Shark Tank. Inventor of the Infomercial, Shark on Shark Tank, Fortune 100 Investor, Philanthropist, Author; Kevin Harrington has done it all. Kevin is one of the principal pioneers of the “As Seen On TV” Industry. As the owner of AsSeenOnTV Inc. and AsSeenOnTv.com, Kevin has launched over 1,000 products in over 100 countries in dozens of languages, creating over $6 Bln in global sales. Gerry David - Former CEO of Celsius™ Kevin isn’t the only household name that has jumped in to lend early support to the development of UNBUZZD™. Gerry David joined Kevin on the FSD Advisory Board in March. Mr. David is best known for his five-year tenure as CEO at zero-calorie fitness drink maker Celsius Holdings, Inc. where he spearheaded a turnaround that resulted in a global sales explosion, influx of capital from notable strategic investors, and a rise in market capitalization that increased shareholder value 35-fold by exceeding $9 Bln. John Duffy Jr. - Former Vice President of National Sales at Coca-Cola Mr. Duffy is a strategy-driven and results-oriented Executive with an MBA and 20+ years of successful experience in sales leadership, revenue growth, strategy optimization, administration, customer development, and operations. Mr. Duffy is a proven leader with excellent communication and organizational skills that were used to manage over $1 Bln in annual revenue. Most recently, John was EVP and Chief Commercial Officer at Legends Access LLC having created and managed its influencer social media and e-commerce platforms and developed partnerships with new clients, including MillerCoors, UPS and Capital One. Previously, John spent 10 years at Coca-Cola starting as Vice President of Marketing Assets and then as Vice President of National Sales. John was responsible for Coca-Cola systems’ largest foodservice distributor, Sysco and over $1 Bln revenue. Massive Expansion Planned Ahead For Shareholder Growth... FSD Pharma continues its R&D activities to develop novel formulations for alc∙ohol misuse dis∙orders and continues the development of such treatments for use in the healthcare sector. FSD maintains a portfolio of strategic invest∙ments through its wholly-owned subsidiary, FSD Strategic Inves∙tments Inc., which represent lo∙ans secured by residential or commercial property. #1 Breaking News Catalyst For Enormous Upside Share Potential FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum TORONTO, ON / ACCESSWIRE / March 5, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative ass∙ets and biotech solutions, today announced its participation in Americas Committee for Treatment and Research in Multiple Sclerosis ("ACTRIMS") 2024 Forum held during Feb. 29 - Mar 2, 2024, in West Palm Beach, Florida. ACTRIMS was founded in 1995 and is comprised exclusively of Multiple Sclerosis ("MS") researchers, clinicians and key stakeholders. The annual conference is the largest of its kind in North America in MS. Represented by senior Research and Clinical development team and co-authored by several of its esteemed scientific advisors, the Company shared the results of Phase-1 clinical study in a poster presentation, "Lucid-21-302 (Lucid-MS) for Protecting Myelin and Neurons and Preventing Disease Progression in Multiple Sclerosis: First-In-Human Phase-1 Dose Escalation Study in Healthy Volunteers". This presentation detailed the final results including adverse events profile of Lucid-21-302 in the single-ascending dose (SAD) studies. The study concluded that Lucid-21-302 is safe and well-tolerated in the dose range of 50-300 mg p.o. administered once, with no difference in pharmacokinetics between the fed and fasted states. There were no SAEs, and most AEs (7/12) in participants receiving Lucid-21-302 were characterized as unlikely related or unrelated to study dr∙ug. In the dose range 50-300 mg, dr∙ug exposure was proportional to dose of the dr∙ug. It also demonstrated good oral absorption with AUC at 300mg comparable to AUC in mouse efficacy studies. Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of MS. It is a patented New Chemical Entity that has shown in preclinical models to prevent demyelination, a known cause of MS and other neurogenerative diseases characterized by damage to the myelin sheath surrounding nerve fibers in the central nervous system. #2 Breaking News Catalyst For Enormous Upside Share Potential FSD Pharma Signs Agreement with Ingenu CRO to Conduct a Clinical Trial to Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage Unbuzzd(TM) TORONTO, ON / ACCESSWIRE / February 26, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative ass∙ets and biotech solutions, today announced that through its subsidiary, HUGE Biopharma Australia Pty Ltd., it entered into an agreement with Ingenu CRO Pty Ltd on February 19, 2024 to conduct "A Randomized, Double-Blind, Plac∙ebo-Controlled Crossover Study to Assess the Safety and Efficacy of unbuzzd™ in Healthy Volunteers in an Induced State of Alc∙ohol Intox∙ication (METAL-1 TRIAL)". This trial is an important step to further verify that the effects of drinking unbuzzd™ helps a person so∙ber up faster from the effects of alc∙ohol. FSD Pharma's proprietary dietary supplement product is called unbuzzd™. unbuzzd™ is a fortified oral liquid formula that potentially enhances cognition, replenishes cofactors needed for alc∙ohol metabolism, and may accelerate the rate of alc∙ohol metabolism in the body allowing a person to so∙ber up faster. Celly Nutrition Corp. ("Celly Nu"), led by beverage and marketing icons Gerry David, former CEO of Celsius, John Duffy former executive of Coca Cola and Kevin Harrington formerly on Shark Tank. Celly Nu is the holder of exclusive rights to FSD Pharma's technology for the recreational sale and use market. Separately FSD Pharma continues to develop a me∙dical based product to accelerate the rate of alc∙ohol metabolism for use in hospitals, me∙dical centres and for front line workers. FSD Pharma (NASDAQ: HUGE) – Targeting Multi-Bln-Dlr Markets with Unmet Needs; Initiate with a Buy rating & $6.00 Target Price [ See Analyst Prediction of 650% Upside Here ]( FSD Pharma< Inc. (NASDAQ: HUGE) Investment Highlights - WORLD-CLASS PIPELINE focused on multi-bln-dlr markets, unmet need, decades of research de-risk our dr∙ugs - WORLD-CLASS PIPELINE focused on multi-bln-dlr markets, unmet need, decades of research de-risk our dr∙ugs - MASSIVE UNIQUE oppor∙tunity with alc∙ohol misuse product; recently added John Duffy (22 years at Coca-Cola) and Gerry David (original Celsius CEO) - ELITE TEAM of scientists with dr∙ug discovery and pharm∙aceutical expertise FSD Pharma, Inc. (NASDAQ: HUGE) Has An Incredible Leadership Team John Duffy spent over 22 years in the Coca-Cola (NYSE: KO) system including roles of increasing responsibilities across multiple functions. In his last role at Coca-Cola as Vice President of National Sales, John led the customer management team responsible for the Coca-Cola systems’ largest foodservice distributor, Sysco. Gerry David is best known for his five-year tenure as Chief Executive Officer at zero-calorie fitness drink maker Celsius Holdings, Inc. (NASDAQ: CELH) where he spearheaded a turnaround that resulted in a global sales explosion, influx of capital from notable strategic inve∙stors, and a rise in market capit∙alization that increased shareholder va∙lue 35-fold by exceeding $9 Bln. Kevin Harrington is the inve∙ntor of the infomercial, Shark on Shark Tank, For∙tune 100 investor, philanthropist, and author. Kevin has launched over 1,000 products in over 100 countries in dozens of languages, creating over $6 Bln in global sa∙les, and was instrumental in the creation of Celsius’ influencer marketing program. FSD Pharma, Inc. (NASDAQ: HUGE) Multiple Wall Street Analyst Predict Triple-Digit Move To The Upside Immediately [Singular Research Analyst Predicts This $.80/Pharma]( [Stock as $6 Target Price]( FSD Pharma, Inc. is poised to evolve from a non-rev∙enue generating emerging growth stock into one that enjoys major growth with an innovative product in a multi-bln industry while simultaneously developing a novel lead MS dr∙ug candidate, also representing a multi-bln industry. While we forecast operating losses ahead, these losses largely reflect increased R&D expenses. Still, for an early rev∙enue company, and especially one with typical heavy biopharmaceutical R&D co∙sts, the bala∙nce sheet is pretty impressive. [ See Analyst Prediction of 650% Upside Here ]( I'm urging my entire 10X Community to pay very close attention to FSD Pharma, Inc. (NASDAQ: HUGE) come Monday morning. Yours for greater gains, Kevin Vander Publisher, 10XProTrader.com Investment Research You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not except stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.